Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of the combination of percutaneous transluminal angioplasty and pharmacological thrombolysis on hemodialysis patients

Liwen Yang , Fengying Tang, Weiqiang Zhong

Department of Nephrology, Huizhou Municipal Central Hospital, China;

For correspondence:- Liwen Yang Email: vu908f@163.com Tel:+8615119086958

Accepted: 26 January 2022 Published: 28 February 2021

Citation: Yang L, Tang F, Zhong W. Effect of the combination of percutaneous transluminal angioplasty and pharmacological thrombolysis on hemodialysis patients. Trop J Pharm Res 2022; 21(2):409-416 doi: 10.4314/tjpr.v21i2.26

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To examine the efficacy of percutaneous transluminal angioplasty (PTA), combined with pharmacologic thrombolysis (PT) on thrombosis of autologous arteriovenous fistulas (AVFs), inflammatory factors, and β₂ microglobulin (β₂-MG) levels in hemodialysis patients.

Methods: Seventy-eight patients with AVF thrombosis allocated randomly into a control group (CG) received PTA, and a study group (SG) received PTA combined with PT (n = 39 in each). The patency, vascular condition, inflammatory factors, viz, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP)), β₂-MG levels, vascular-related factors (VEGF-A and MCP-1), complications, and quality of life were determined.

Results: At three and six months after surgery, t SG exhibited a higher vascular patency than CG (p < 0.05). Serum levels of IL-6, hs-CRP, β₂-MG, VEGF-A, and MCP-1 of t SG were lower than those of CG (p < 0.05). The SG showed higher cross-sectional area, inner diameter at the site of fistula, and better quality of life scores than CG (p < 0.05).

Conclusion: The combination of PTA and PT enhances efficacy, increases vascular patency, reduces inflammatory response, lowers the level of β₂-MG, and improves quality of life in patients with AVFs without increasing complications. Thus, the combination treatment has potentials for the management of hemodialysis patients

Keywords: Hemodialysis, Percutaneous transluminal angioplasty, Arteriovenous endovascular fistula, Thrombosis, Pharmacological thrombolysis, Inflammatory factor